Adenosine A2A receptor antagonists for Parkinson's disease rationale, therapeutic potential and clinical experience

Drugs and Aging

Volumn 22, Issue 6, 2005, Pages 471-482

  Hauser, Robert A ^a   Schwarzschild, Michael A ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; CAFFEINE; ISTRADEFYLLINE; LEVODOPA; PLACEBO; ADENOSINE A2A RECEPTOR; PURINE DERIVATIVE;

BASAL GANGLION; CLINICAL TRIAL; DEGENERATION; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DYSKINESIA; HEADACHE; HUMAN; LABORATORY TEST; MODEL; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE STIFFNESS; NAUSEA; NEUROBIOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; SYMPTOM; TREATMENT INDICATION; VOMITING; AGED; BIOLOGICAL MODEL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; HUMANS; MODELS, BIOLOGICAL; PARKINSON DISEASE; PURINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ADENOSINE A2A; TREATMENT OUTCOME;

EID: 22344455811     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522060-00002     Document Type: Review

References (50)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58
2. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-91
3. Kase H, Richardson P, Jenner P, editors. Adenosine receptors and Parkinson's disease. San Diego (CA): Academic Press, 2000
4. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 2005; 105: 267-310
5. Cunha RA. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int 2002; 38: 107-25
6. Tohyama M, Takatsuji K. Atlas of neuroactive substances and their receptors in the rat. Oxford: Oxford University Press, 1998
7. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003; 61: 293-6
8. 2A antagonist istradefylline in advanced PD. Neurology 2003; 61: 297-303
9. Stacy MA, the US-005 and US-006 Investigator Group. Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson's disease: a positive safety profile with supporting efficacy [abstract]. Mov Disord 2004; 19 Suppl. 9: S215-S6
10. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-75
11. 2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003; 61 (11 Suppl. 6): S97-S100
12. Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 2003; 91: 9-18
13. Fink JS, Weaver DR, Rivkees SA, et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992; 14: 186-95
14. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991; 57: 1062-7
15. Ochi M, Koga K, Kurokawa M, et al. Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000; 100: 53-62
16. 2A receptors in amphetamine sensitization. Neuropsychopharmacology 2005 May; 30 (5): 891-900
17. Pinna A, Di Chiara G, Wardas J, et al. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 1996; 8: 1176-81
18. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 1997; 321: 143-7
19. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 2000; 408: 249-55
20. 2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 2000; 12: 4033-7
21. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001; 39: 233-8
22. 2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 1994; 256: 263-8
23. Hauber W, Nagel J, Sauer R, et al. Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen. Neuroreport 1998; 9: 1803-6
24. Shiozaki S, Ichikawa S, Nakamura J, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999; 147: 90-5
25. Wardas J, Konieczny J, Lorenc-Koci E. SCH 58261, an A2A adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 2001; 41: 160-71
26. Correa M, Wisniecki A, Betz A, et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 2004; 148: 47-54
27. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 2004; 189: 182-8
28. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43: 507-13
29. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999; 52: 1673-7
30. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkin-sonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000; 162: 321-7
31. Hernan MA, Takkouche B, Caamano-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-84
32. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283: 2674-9
33. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001; 50: 56-63
34. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000; 55: 1350-8
35. Ascherio A, Chen H, Schwarzschild MA, et al. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003; 60: 790-5
36. Ascherio A, Weisskopf MG, O'Reilly EJ. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004; 160: 977-84
37. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143, 1-6
38. Xu K, Xu Y-H, Chen J-F, et al. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett 2002; 322: 13-6
39. Joghataie MT, Roghani M, Negahdar F, et al. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 2004; 10: 465-8
40. Oztas E, Kalda A, Xu K, et al. Caffeine attenuates MPTP induced loss of dopaminergic neurons in substantia nigra in mice. Program No. 487.6. Washington, DC: Society for Neuroscience, 2002
41. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002; 80: 262-70
42. Pierri M, Vaudano E, Sager T, et al. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005 Mar; 48 (4): 517-24
43. Ledent C, Vaugeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997; 388: 674-8
44. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999; 19: 9192-200
45. Fredduzzi S, Moratalla R, Monopoli A, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002; 22: 1054-62
46. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003; 184: 285-94
47. 2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 2002; 46: 251-7
48. Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem 2003; 84: 1398-410
49. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in Parkinson's disease patients with motor fluctuations and dyskinesia. J Clin Neuropharmacol 2000; 23: 75-81
50. LeWitt PA, US-005/US-006 Clinical Investigator Group. 'Off' time reduction from adjunctive use of istradefylline (KW-6002) in levodopa-treated patients with advanced Parkinson's disease [abstract]. Mov Disord 2004; 19 Suppl. 9: S222